Interim Report January-March 2017
“New top-line Phase 3 results support the longterm safety and efficacy of CAM2038 in patients with opioid dependence. After completing presubmission meetings with EMA and FDA, market approval applications for CAM2038 are now being finalized.”Business highlights first quarter 2017 · All patients completed treatment in Phase 3 long-term safety study of long-acting buprenorphine depots in opioid dependent patients. · Pre-MAA/NDA meetings held with EMA and FDA for weekly and monthly buprenorphine depots for treatment of opioid use disorder. · Presentation of Phase 2 results for long-